Faculty of Medicine, Prince of Songkla University
Songkhla, 90110, Thailand
NCT Number: NCT06831786
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Early Phase 1
Songkhla, 90110, Thailand
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administering a booster dose of the bivalent mRNA vaccine BNT162b2
Administering a VaxigripTetra™
Time frame: Before vaccination
IFN-γ response against the SARS-CoV-2 virus, measured by the ELISpot assay
Time frame: 4 weeks post vaccination
IFN-γ response against the SARS-CoV-2 virus, measured by the ELISpot assay
Time frame: before vaccination
IgG response against the SARS-CoV-2 virus, measured by ELISA.
Time frame: 4 weeks post vaccination
IgG response against the SARS-CoV-2 virus, measured by ELISA.
Prince of Songkla University
Other
Immunogenicity to SARS-CoV-2 of Co-administering Bivalent mRNA BNT162b2 Booster and Quadrivalent Influenza Vaccine Among Healthy Volunteers: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07599449
COVID - 19, COVID-19
Paris, France
View Trial DetailsNCT07287137
COVID - 19, COVID -19
Bethesda, Maryland, United States
View Trial DetailsNCT07030075
COVID - 19, COVID-19
Lusaka, Lusaka Province, Zambia
View Trial DetailsNCT07711444
Behavior, Behavioral Symptoms
Taichung, Taiwan
View Trial Details